Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Valero

Showing results (81-90 of 118) with videos related to

Pageof 12
Sort By:
British Journal of Cancer|September 30, 2010
Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patientsY C Cheng, V Valero, M L Davis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 11, 2012
Multifocality and multicentricity in breast cancer and survival outcomesS P Lynch, X Lei, M Chavez-MacGregor, et al.
Journal of the National Cancer Institute. Monographs|January 1, 1993
The M. D. Anderson Cancer Center experience with Taxol in metastatic breast cancerF A Holmes, V Valero, R S Walters, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1995
Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancerV Valero, F A Holmes, R S Walters, et al.
American Journal of Surgery|February 13, 2002
Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinomaH M Kuerer, S E Singletary, A U Buzdar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1996
Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancerF A Holmes, T Madden, R A Newman, et al.
The British Journal of Surgery|February 22, 2018
Baseline factors predicting a response to neoadjuvant chemotherapy with implications for non-surgical management of triple-negative breast cancerR F D van la Parra, A B Tadros, C M Checka, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 24, 2015
Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancerV Diéras, M Campone, D A Yardley, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 17, 1999
Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I resultsF A Holmes, V Valero, R S Walters, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2001
Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancerE Rivera, V Valero, L Syrewicz, et al.
Pageof 12

Showing results (81-90 of 118) with videos related to

Sort By:
Pageof 12
British Journal of Cancer|September 30, 2010
Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patientsY C Cheng, V Valero, M L Davis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 11, 2012
Multifocality and multicentricity in breast cancer and survival outcomesS P Lynch, X Lei, M Chavez-MacGregor, et al.
Journal of the National Cancer Institute. Monographs|January 1, 1993
The M. D. Anderson Cancer Center experience with Taxol in metastatic breast cancerF A Holmes, V Valero, R S Walters, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1995
Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancerV Valero, F A Holmes, R S Walters, et al.
American Journal of Surgery|February 13, 2002
Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinomaH M Kuerer, S E Singletary, A U Buzdar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1996
Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancerF A Holmes, T Madden, R A Newman, et al.
The British Journal of Surgery|February 22, 2018
Baseline factors predicting a response to neoadjuvant chemotherapy with implications for non-surgical management of triple-negative breast cancerR F D van la Parra, A B Tadros, C M Checka, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 24, 2015
Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancerV Diéras, M Campone, D A Yardley, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 17, 1999
Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I resultsF A Holmes, V Valero, R S Walters, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2001
Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancerE Rivera, V Valero, L Syrewicz, et al.
Pageof 12